Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 162

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 162
---
 Position        |   | Year       |   | -$     |   |   | -$    |   | -$     |   | -$           |   | -$     |   | -$           |   | -$    |
| Chris Kim, Chief Executive Officer |   | 12/31/2024 | ​ | $      | ​ |   | —     |   | —      |   | —            |   | —      |   | —            |   |       |
| ​                                  |   | 12/31/2023 | ​ | $      | ​ |   | —     |   | —      |   | —            |   | —      | ​ | —            | ​ | ​     |

| (1) | These amounts reflect the grant date market value as required by Regulation S-K Item 402(n)(2), computed in accordance with FASB ASC Topic 718. |

Executive Compensation Arrangements As of December 31, 2024 and 2023, the Company has $0.2 million due to Chris Kim, our Chief Executive Officer, for compensation under his compensation agreement. Other than the compensation agreement described above, the Company has no other executive compensation, change in control or similar agreements or arrangements. 2025 Omnibus Equity Incentive Plan The Company has adopted the 2025 Omnibus Equity Incentive Plan, which plan was approved by stockholders at the extraordinary general meeting. The purpose of the Incentive Plan is to help us attract, motivate and retain such persons with awards designed for the U.S. market and thereby enhance stockholder value. Administration. The Incentive Plan will be administered by a committee designated by the Company Board (“Plan Committee”). The Plan Committee will have the power to determine, among other items, the terms of the awards granted under the Incentive Plan, including the exercise price, the number of shares subject to each award (and the class of shares), and the exercisability and vesting terms of the awards. The Plan Committee also will have the power to determine the persons to whom and the time or times at which awards will be made and to make all other determinations and take all other actions advisable for the administration of the Incentive Plan. All decisions made by the Plan Committee pursuant to the provisions of the Incentive Plan will be final, conclusive and binding. To the extent desirable to qualify transactions under the Incentive Plan as exempt under Rule 16b-3 of the Exchange